Praveen Kumar Reddy Nagireddy Selected Research

Noscapine (Narcotine)

1/2022	In silico design of novel tubulin binding 9-arylimino derivatives of noscapine, their chemical synthesis and cellular activity as potent anticancer agents against breast cancer.
1/2022	9-Ethynyl noscapine induces G2/M arrest and apoptosis by disrupting tubulin polymerization in cervical cancer.
1/2021	Rational design of 9-vinyl-phenyl noscapine as potent tubulin binding anticancer agent and evaluation of the effects of its combination on Docetaxel.
11/2020	9-PAN promotes tubulin- and ROS-mediated cell death in human triple-negative breast cancer cells.
10/2020	Tubulin- and ROS-dependent antiproliferative mechanism of a potent analogue of noscapine, N-propargyl noscapine.
11/2019	Imidazo[2,1-b]thiazole-Coupled Natural Noscapine Derivatives as Anticancer Agents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Praveen Kumar Reddy Nagireddy Research Topics

Disease

5	Neoplasms (Cancer) 01/2022 - 11/2019
3	Breast Neoplasms (Breast Cancer) 01/2022 - 11/2020
2	Triple Negative Breast Neoplasms 11/2020 - 10/2020
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 11/2019

Drug/Important Bio-Agent (IBA)

6	Noscapine (Narcotine)IBA 01/2022 - 11/2019
4	TubulinIBA 01/2022 - 11/2019
2	Antitussive Agents (Antitussives)FDA Link 01/2022 - 01/2021
2	AlkaloidsIBA 01/2022 - 01/2022
1	isoquinolineIBA 01/2022
1	phthalideIBA 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 01/2022
1	LatexIBA 01/2022
1	Docetaxel (Taxotere)FDA Link 01/2021
1	N-propargylIBA 10/2020
1	lissamine rhodamine B (sulforhodamine B)IBA 10/2020
1	Pharmaceutical PreparationsIBA 10/2020
1	Proteins (Proteins, Gene)FDA Link 11/2019

Therapy/Procedure

1	Therapeutics 01/2021